HOFFMAN ESTATES, Ill., June 21, 2005 -- Siemens announced today it has formed a new division called Siemens Medical Solutions Molecular Imaging, which combines its nuclear medicine operations with CTI Molecular Imaging, Inc. - the world's leading provider of positron emission technology (PET) imaging equipment and services, and now a wholly owned subsidiary of Siemens Medical Solutions.

With this completed acquisition and the formation of a division focused on PET and single photon emission computed tomography (SPECT)-based molecular imaging technologies, Siemens continues and strengthens its commitment to molecular imaging development, technological innovation and the creation of dynamic new technologies that will revolutionize the diagnosis and treatment of disease. This includes the development and distribution of molecular biomarkers, preclinical imaging for research and pharmaceuticals, and application and post-processing for molecular imaging.

"Uniting Siemens Nuclear Medicine with CTI to form a new molecular imaging division supports our vision to be the innovation trendsetter in the healthcare industry," said Erich Reinhardt, Ph.D., president and CEO, Siemens Medical Solutions. "By strengthening our leadership position in identifying disease earlier at the molecular level, we continue to transform the delivery of healthcare by improving patient care while reducing costs."
Leading Siemens Medical Solutions Molecular Imaging will be Michael Reitermann, president of the former Siemens Nuclear Medicine division. Ronald Nutt, Ph.D., founder and former president and CEO of CTI Molecular Imaging, is now the chief scientific advisor of the new Siemens division.

"Siemens and CTI have had a long-standing partnership through our joint venture, CTI PET Systems (CPS), so joining together to form Siemens Medical Solutions Molecular Imaging is a natural progression in our relationship," said Reitermann. "Together, we will give our customers access to the leading PET and SPECT technology, and will expand and build on CTI's broad know-how in the field of molecular diagnostics."

"CTI and Siemens are two pioneering companies in the healthcare technology field," said Nutt. "This new partnership marks an exciting step in our quest to discover and pursue new paths in molecular medicine, and reflects our overall strategy to personalize healthcare and positively impact the way illness is identified and treated."

More Industry Headlines